AbClon (174900) Fundamentals 2026 — Revenue Analysis | SniperIQ
AbClon (174900) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩391.7B, trading at ₩19660.00 on the KOE. This SniperIQ fundamentals page covers AbClon's valuation, profitability (net margin -313.2%), revenue (₩4.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AbClon's market cap?
AbClon (174900) has a market capitalization of approximately ₩391.7B, trading at ₩19660.00 on the KOE. Market cap moves with the live share price.
What is AbClon's P/E ratio?
AbClon's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AbClon?
AbClon runs a net profit margin of -313.2%, a gross margin of 22.5%, and an operating margin of -320.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AbClon generate?
AbClon reported revenue of ₩4.7B for fiscal year 2025, with net income of -₩17.9B and earnings per share (EPS) of -965.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AbClon pay a dividend?
AbClon does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is AbClon financially healthy?
AbClon carries a debt-to-equity ratio of 0.13x and a current ratio of 4.88x, with a market beta of 0.74. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AbClon a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AbClon (174900) the key facts are: market cap ₩391.7B, revenue ₩4.7B, 52-week range 9770-95800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AbClon's full fundamentals live
Get AbClon's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.